BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 78529)

  • 1. Flutamide therapy for carcinoma of the prostate.
    Airhart RA; Barnett TF; Sullivan JW; Levine RL; Schlegel JU
    South Med J; 1978 Jul; 71(7):798-801. PubMed ID: 78529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer.
    Jacobo E; Schmidt JD; Weinstein SH; Flocks RH
    Urology; 1976 Sep; 8(3):231-3. PubMed ID: 788293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D
    J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced prostatic cancer with flutamide.
    Sanford EJ; Bowditch RR; Rohner TJ; Bardin CW
    Pa Med; 1979 Sep; 82(9):29-31. PubMed ID: 386212
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flutamide therapy for advanced prostatic cancer: a phase II study.
    MacFarlane JR; Tolley DA
    Br J Urol; 1985 Apr; 57(2):172-4. PubMed ID: 3986452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.
    Lund F; Rasmussen F
    Br J Urol; 1988 Feb; 61(2):140-2. PubMed ID: 3280080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
    N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience with flutamide in patients with prostatic carcinoma.
    Prout GR; Keating MA; Griffin PP; Schiff SF
    Urology; 1989 Oct; 34(4 Suppl):37-45; discussion 46-56. PubMed ID: 2800092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
    Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with flutamide in previously untreated patients with advanced prostatic cancer.
    Sogani PC; Whitmore WF
    J Urol; 1979 Nov; 122(5):640-3. PubMed ID: 501817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G
    Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
    Sogani PC; Vagaiwala MR; Whitmore WF
    Cancer; 1984 Aug; 54(4):744-50. PubMed ID: 6378356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of flutamide in the treatment of carcinoma of the prostate stages C and D (T3-T4, Nx-N0, M0-M1 categories)].
    Daricello G; Caramia G; Rizzo FP; Serretta V; Di Trapani D; Pavone-Macaluso M
    Minerva Urol Nefrol; 1986; 38(1):71-6. PubMed ID: 3738681
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M; Serretta V; Daricello G; Pavone C; Cacciatore M; Romano C; Cavallo N
    Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flutamide as primary treatment for metastatic prostatic cancer.
    Lundgren R
    Br J Urol; 1987 Feb; 59(2):156-8. PubMed ID: 3828712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.